October 07, 2021 CytoDyn Announces Study to Eval
Post# of 155256
(Total Views: 490)
Posted On: 07/06/2025 10:29:47 AM
October 07, 2021
CytoDyn Announces Study to Evaluate Potential Synergistic Effects of Leronlimab with Immune Checkpoint Blockade (ICB)
Clinical Trial Development Targeting Triple-Negative Breast Cancer (TNBC) to Evaluate Anti-Tumor Effects and Identify Immunological Biomarkers for Leronlimab in Combination with Immune Checkpoint Blockade
VANCOUVER, Washington, Oct. 07, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced a study for treating triple-negative breast cancer (TNBC) with leronlimab in a humanized TNBC xenograft model. This investigator-initiated study is being led by Jangsoon Lee, Ph.D., assistant professor of Breast Medical Oncology Research at The University of Texas MD Anderson Cancer Center.
The study is intended to determine the potential synergistic therapeutic efficacy of leronlimab in combination with immune checkpoint blockade (ICB) to attempt to raise the standard of care for breast cancer patients.
___
Sept. 2024 shareholder letter:
I am pleased to announce that CytoDyn is working with a team of experts to resume the exploration of Triple-Negative Breast Cancer (“TNBC”), including colleagues from the University of Hawaii Cancer Center, MD Anderson Cancer Center, and the Pennsylvania Cancer and Regenerative Medicine Research Center. We will be working with this team in the coming months to design and conduct a preclinical TNBC study that will aim to confirm the mechanism of action of leronlimab in oncology and address the question of potential synergies with both antibody-drug conjugates and immune checkpoint inhibitors.
___
May 13th, 2025:
Survival observations in mTNBC patients correlated with increased PD-L1 expression
Preliminary evidence suggests leronlimab has potential to turn “cold” tumors “hot”
__
2025,
MD Anderson talent has migrated to Cytodyn
Upregulating -- a whole new world of possibilites
CytoDyn Announces Study to Evaluate Potential Synergistic Effects of Leronlimab with Immune Checkpoint Blockade (ICB)
Clinical Trial Development Targeting Triple-Negative Breast Cancer (TNBC) to Evaluate Anti-Tumor Effects and Identify Immunological Biomarkers for Leronlimab in Combination with Immune Checkpoint Blockade
VANCOUVER, Washington, Oct. 07, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced a study for treating triple-negative breast cancer (TNBC) with leronlimab in a humanized TNBC xenograft model. This investigator-initiated study is being led by Jangsoon Lee, Ph.D., assistant professor of Breast Medical Oncology Research at The University of Texas MD Anderson Cancer Center.
The study is intended to determine the potential synergistic therapeutic efficacy of leronlimab in combination with immune checkpoint blockade (ICB) to attempt to raise the standard of care for breast cancer patients.
___
Sept. 2024 shareholder letter:
I am pleased to announce that CytoDyn is working with a team of experts to resume the exploration of Triple-Negative Breast Cancer (“TNBC”), including colleagues from the University of Hawaii Cancer Center, MD Anderson Cancer Center, and the Pennsylvania Cancer and Regenerative Medicine Research Center. We will be working with this team in the coming months to design and conduct a preclinical TNBC study that will aim to confirm the mechanism of action of leronlimab in oncology and address the question of potential synergies with both antibody-drug conjugates and immune checkpoint inhibitors.
___
May 13th, 2025:
Survival observations in mTNBC patients correlated with increased PD-L1 expression
Preliminary evidence suggests leronlimab has potential to turn “cold” tumors “hot”
__
2025,
MD Anderson talent has migrated to Cytodyn
Upregulating -- a whole new world of possibilites
(5)
(0)